24Sep 2025

Holy Stone Healthcare (HSHC) has once again won the Innovation award at the 2025 Taipei Biotech Awards. After years of dedicated research and development, HSHC has advanced its targeted, controlled biopolymer drug delivery system into the HylX drug delivery platform, designed to deliver therapeutics across key biological barriers to the brain, eye, and tumors.

 

read more
17Jun 2025
Boston, USA-June 16. 2025–HSHC is participating in the BIO International Convention (USBIO 2025) held in Boston from June 16 to June 19, presenting our HylX drug delivery platform and assets. During the event, we engage in partnership discussions with global pharmaceutical companies
read more
14May 2025
Kobe, Japan-May 14. 2025 -Holy Stone Health Care (HSHC) presented its proprietary HylX drug delivery technology platform at the 12th international Symposium of Drug Delivery System (SDDS 2025).
read more

Vision & Mission

We are committed to developing lifesaving therapeutics and targeted delivery technologies to improve the quality of life of patients worldwide. Our mission is to create innovative therapeutic products based on hyaluronic acid using our know-how and experience to address unmet clinical needs with superior tolerability and efficacy.

Research Research High Quality High Quality Patent Rights Patent Rights

Assets

We are focused on development of new drug, especially hyaluronic acid related therapeutic products.

see more